Chemical Compound

Mra-CN

CAS Registry Number 88254-07-3
Back to search Request a Quote
Mra-CN chemical structure
Primary Record

Mra-CN

In stock
4,663 g
Purity
98.1 %
CAS
88254-07-3

Compound Identifiers & Properties

CAS
88254-07-3
PubChem CID
174734
SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N6CCOCC6C#N)O
Canonical SMILES
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N2CCOCC2C#N)[C@H](O)[C@H](C)O1

Names & Synonyms

  • Mra-CN
  • Cyanomorpholinoadriamycin
  • cyanomorpholino doxorubicin
  • MRA CN
  • Cyanomorpholinodoxorubicin
  • AC1L5BJS
  • RefChem:919315
  • 3'-3CN-4morphAdriamycin
  • DTXSID901310564
  • CCRIS 5080
  • SCHEMBL3342594
  • CHEBI:41576
  • YIMDLWDNDGKDTJ-QLKYHASDSA-N
  • DTXCID301740408
  • C32H34N2O12
  • 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin
  • CID174734
  • MRA-CN isomer a, a:b = 93:7
  • NSC357704
  • C32-H34-N2-O12
  • CID:174734
  • NSC 357704
  • 3'-(3-Cyano-4-morpholinyl)-3'-deamino-adriamycin
  • 88254-07-3
  • BRN 6050053
  • A-489
  • 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin
  • 3'-Deamino-3'-(3-cyano-4-morpholinyl)doxorubicin
  • SID:134223680
  • J261.867B
  • A 489
  • 89196-08-7
  • 3'-Deamino-3'-(3-cyano-4-morpholinyl)adriamycin
  • C038555
  • 3'-DESAMINO-3'-(3-CYANO-4-MORPHOLINYL)-DOXORUBICIN
  • Q27120430
  • 3 -Deamino-3 -(3-cyano-4-morpholinyl)adriamycin
  • 4-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile
  • alpha-3'-Deamino-3'-(3-cyano-4-morpholinyl-12-imino-13-dihydroadriamycin
  • (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-(3-cyanomorpholin-4-yl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
  • (8S-cis)-10-((3-((S)-3-Cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • 10-((3-((S)-3-Cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (8S-cis)-
  • 5,12-Naphthacenedione, 10-((3-((S)-3-cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • 5,12-Naphthacenedione, 10-[[3-(3-cyano-4-morpholinyl)-2,3,6-
  • 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin, (S-(8S-cis))-isomer
  • 5,12-Naphthacenedione, 10-((3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-[(3S)-3-cyanomorpholin-4-yl]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
  • (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8beta-(hydroxyacetyl)-10alpha-[[3-(3-cyanomorpholino)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-5,12-naphthacenedione
  • (8S,10S)-10alpha-[[3-(3-Cyano-4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8alpha,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • 4-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]tetrahydropyran-4-yl]morpholine-3-carbonitrile
  • 4-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-{[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl]morpholine-3-carbonitrile
  • 4-[3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile
  • 5,12-Naphthacenedione, 10-[[3-(3-cyano-4-morpholinyl)-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-